REFERENCES
1. Franzen O, Baldus S, Rudolph V, Meyer S, Knap M, et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J 2010;31:1373-81.
2. Kortlandt FA, van ‘t Klooster CC, Bakker AL, Swaans MJ, Kelder JC, et al. The predictive value of conventional surgical risk scores for periprocedural mortality in percutaneous mitral valve repair. Neth Heart J 2016;24:475-80.
3. Díez-villanueva P, Arizá-solé A, Vidán MT, Bonanad C, Formiga F, et al. Recomendaciones de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología para la valoración de la fragilidad en el anciano con cardiopatía. Rev Esp Cardiol 2019;72:63-71.
4. Zuern CS, Bauer A, Lubos E, Boekstegers P, Puls M, et al. Influence of non-cardiac comorbidities on outcome after percutaneous mitral valve repair: results from the German transcatheter mitral valve interventions (TRAMI) registry. Clin Res Cardiol 2015;104:1044-53.
5. Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052-61.
6. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, et al; Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-44.
7. Abellan van Kan G, Rolland YM, Morley JE, Vellas B. Frailty: toward a clinical definition. J Am Med Dir Assoc 2008;9:71-2.
8. Stone GW, Adams DH, Abraham WT, Kappetein AP, Généreux P, et al; Mitral Valve Academic Research Consortium (MVARC). Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 2: endpoint definitions: a consensus document from the mitral valve academic research consortium. J Am Coll Cardiol 2015;66:308-21.
9. Wei CC, Zhang ST, Tan G, Zhang SH, Liu M. Impact of anemia on in-hospital complications after ischemic stroke. Eur J Neurol 2018;25:768-74.
10. Afilalo J. Frailty in patients with cardiovascular disease: why, when, and how to measure. Curr Cardiovasc Risk Rep 2011;5:467-72.
11. Sanchis J, Bonanad C, Ruiz V, Fernández J, García-Blas S, et al. Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome. Am Heart J 2014;168:784-91.
12. Uchmanowicz I, Łoboz-Rudnicka M, Szeląg P, Jankowska-Polańska B, Łoboz-Grudzień K. Frailty in heart failure. Curr Heart Fail Rep 2014;11:266-73.
13. Yanagawa B, Graham MM, Afilalo J, Hassan A, Arora RC. Frailty as a risk predictor in cardiac surgery: Beyond the eyeball test. J Thorac Cardiovasc Surg 2019;157:1905-9.
14. Afilalo J, Lauck S, Kim DH, Lefèvre T, Piazza N, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol 2017;70:689-700.
15. Green P, Woglom AE, Genereux P, Daneault B, Paradis JM, et al. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. JACC Cardiovasc Interv 2012;5:974-81.
16. Metze C, Matzik AS, Scherner M, Körber MI, Michels G, et al. Impact of frailty on outcomes in patients undergoing percutaneous mitral valve repair. JACC Cardiovasc Interv 2017;10:1920-9.
17. White HD, Westerhout CM, Alexander KP, Roe MT, Winters KJ, et al; TRILOGY ACS investigators. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Eur Heart J Acute Cardiovasc Care 2016;5:231-42.
18. Benito-gonzález T, Estévez-loureiro R, Cardona JG, Prado APD, Ruiz MC, et al. Percutaneous treatment of mitral and tricuspid regurgitation in heart failure. In: Akin I, editor. Interventional Cardiology. InTech; 2017.
19. Iliadis C, Lee S, Kuhr K, Metze C, Matzik AS, et al. Functional status and quality of life after transcatheter mitral valve repair: a prospective cohort study and systematic review. Clin Res Cardiol 2017;106:1005-17.
20. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:2307-18.
21. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, et al; MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297-306.
22. Benito-González T, Estévez-Loureiro R, Villablanca PA, Armeni P, Iglesias-Gárriz I, et al. Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure. Cardiovasc Revasc Med 2020;21:52-60.
23. Moretti C, Iqbal J, Murray S, Bertaina M, Parviz Y, et al. Prospective assessment of a palliative care tool to predict one-year mortality in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2017;6:272-9.
24. Ellis G, Gardner M, Tsiachristas A, Langhorne P, Burke O, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017;9:CD006211.
